David Deng
Corporate Officer/Principal bei Verinata Health, Inc.
Profil
David Deng is currently working as the Director of Assay Development at Verinata Health, Inc. Previously, he worked as a Principal at Agilent Technologies, Inc. Dr. Deng holds a doctorate degree from McGill University and undergraduate, graduate, and doctorate degrees from Shanghai Jiao Tong University.
Aktive Positionen von David Deng
| Unternehmen | Position | Beginn |
|---|---|---|
Verinata Health, Inc.
 Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 11.08.2009 |
Ehemalige bekannte Positionen von David Deng
| Unternehmen | Position | Ende |
|---|---|---|
| AGILENT TECHNOLOGIES, INC. | Corporate Officer/Principal | - |
Ausbildung von David Deng
| McGill University | Doctorate Degree |
| Shanghai Jiao Tong University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AGILENT TECHNOLOGIES, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Verinata Health, Inc.
Verinata Health, Inc. Medical/Nursing ServicesHealth Services Verinata Health, Inc. focuses on maternal and fetal health. It develop and offer non-invasive tests for early identification of fetal chromosomal abnormalities. The firm's products include 'verifi' prenatal test, a non-invasive test that detects three primary aneuploidies for trisomies 21, 18 and 13 from a single maternal blood draw as early as 10 weeks and 'Monosomy X', a test for Turner syndrome. The company was founded by Michael D. Grisham and Richard P. Rava in 2001 and is headquartered in San Diego, CA. | Health Services |
